Notwithstanding positive clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable difficulty from pharmacy benefit managers. The insurers are frequently erecting obstacles to coverage, such as steep cost requirements an